Khushal Sudhakarrao Thosare, we are creating a long list of clients
Their study included adults with type 2 diabetes and moderate CVD risk who initiated dulaglutide (35,572), exenatide (4,376), liraglutide (8,843), or semaglutide (33,063) between 2019 and 2021
Treatment risks included weight gain (none, 5%, 10%), added risk of skin rash (none, 10%, 20%), and risk of liver damage (none, 1 in 1000, 10 in 1000)
Will I still need my arthritis medications if I start tirzepatide
Both tirzepatide and semaglutide are GLP-1 receptor agonists used for weight loss and diabetes management
Ibrahim NE, Gaggin HK, Turchin A et al (2019) Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction